Pliant Therapeutics, Inc. · NASDAQ:PLRX
Pliant Therapeutics — ERS Congress 2024
13 slides from Pliant Therapeutics's conference presentation, September 2024
Slide 1: Bexotegrast reduces type 1 collagen deposition in participants with IPF after 12 weeks of therapy
Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy Sydney B. Montesi, Gregory P. Cosgrove, Scott M. Turner, Iris Zhou, Nikos Efthimiou, Antonia Susnjar, Ciprian Catana, Caroline Fromson, Annie Clark, Martin Decaris, Chris
Slide 2: Conflict of Interest Disclosure
Conflict of Interest Disclosure ❑ I have no real or perceived conflicts of interest that relate to this presentation. ❑ I have the following real or perceived conflicts of interest that relate to this presentation: Affiliation / Financial interest Commercial company Grants/research support: Boehring
Slide 3: Background and Objectives
Background and Objectives αvβ6 and αvβ1 Integrins Promote Fibrosis Through Activation of TGF-β1 • IPF is primarily a basilar, subpleural disease characterized by excessive deposition of type 1 collagen2 Bexotegrast (PLN-74809) • In patients with IPF, αvβ6 and αvβ1 integrins are overexpressed in the
Slide 4: Study Design and Participant Demographics
Study Design and Participant Demographics Baseline Demographics Inclusion Criteria Bexotegrast Placebo Bexotegrast 160 mg (n=7) • IPF diagnosis ≤8 years (n=7)a (n=3) R • FVCpp ≥45% Placebo (n=3) 2:1 Mean age, • DLCO ≥30% 69.1 74.0 years • eGFR ≥50 mL/min Stratified for use of background therapy (nin
Slide 5: Bexotegrast Reduced Type I Collagen in the Lung Using PET Imaging After 12 Weeks
Bexotegrast Reduced Type I Collagen in the Lung Using PET Imaging After 12 Weeks Bexotegrast 160 mg (n=7) Placebo (n=3) 0.173 0.097 (14.0%) 0.074 0.12 (7.5%) (6.57%) (9.2%) −0.015 (−1.2%) −0.030 (− 2.5%) −0.080 −0.044 (− 2.8%) (− 6.0%) Bexotegrast 160 mg reduced the 68Ga-CBP8 PET SUVs from baseline,
Slide 6: Bexotegrast Reduced Type I Collagen in the Lung After 12 Weeks
Bexotegrast Reduced Type 1 Collagen in the Lung After 12 Weeks Baseline Week 12 Bexotegrast Participant A: bexotegrast 160 mg • Decrease from baseline to Week 12 in top quartile 68Ga-CBP8 SUV of −0.17 SUV • Change in top quartile SUV of −15.5% 1.3 Placebo 0 Participant B: placebo • Increase from bas
Slide 7: Slower Dynamic Changes in Extracellular Volume Based on DCE-MRI Parameters Observed With Bexotegrast
Dynamic Changes in Extracellular Volume Based on DCE-MRI Parameters Observed With Bexotegrast Bexotegrast 160 mg (n=6) Placebo (n=3) Peak Enhancement kwashout 12.0% (10.0%) 0.07 %/min Slower (0.8%) Faster −21.0% (−16.1%) − 1.06 %/min (31.7%) Reduced peak enhancement has been associated with Slower k
Slide 8: Changes in 68Ga-CBP8 SUV Correlated With Changes in Lung Function and Improved Cough Severity
Changes in 68Ga-CBP8 SUV Correlated With Changes in Lung Function and Improved Cough Severity FVC Cough Severity 150 60 LS Mean (SE) Change From Mean (SE) Change From 100 Baseline in VAS Score Baseline in FVC (mL) 40 +40.3 50 0 +14.5 20 -50 106 mL 0 -100 −91.5 -20 -150 Bexotegrast 160 mg (n=7) Bexot
Slide 9: Reduced Prognostic IPF Biomarkers
Bexotegrast Reduced Prognostic IPF Biomarkers PRO-C3 ITGB6 4 10 1.76 LS Mean (SE) Change From Baseline LS Mean (SE) Change From Baseline 8 3.567 2 6 in PRO-C3 (ng/mL) in ITGB6 (pg/mL) 4 0 2 0 -2 −1.68 -2 −0.148 -4 -4 Bexotegrast Placebo Bexotegrast Placebo 160 mg (n=3) 160 mg (n=3) (n=7) (n=7) Circu
Slide 10: Bexotegrast Was Well Tolerated Over 12 Weeks
Bexotegrast Was Well Tolerated Over 12 Weeks Bexotegrast Placebo TEAE, n (%) (n=7) (n=3) TEAE 6 (85.7) 1 (33.3) TEAE related to study drug 5 (71.4) 1 (33.3) Serious TEAE 0 0 TEAE leading to interruption of study drug 1 (14.3)a 0 TEAE leading to withdrawal from study 0 0 TEAE leading to early termina
Slide 11: Conclusions
Conclusions Changes in type 1 collagen PET imaging with 68Ga-CBP8 and DCE-MRI support antifibrotic effects of bexotegrast, suggesting favourable lung remodelling Treatment with bexotegrast numerically improved FVC, cough severity, and prognostic biomarkers, suggesting its potential for disease modif
Slide 12: ERS Congress 2024, 7-11 September, Vienna, Austria
@ ERS CONGRESS | 2024 7-11 September | Vienna, Austria
Slide 13: Reference List
Reference List 1 Decaris ML, et al. Respir Res. 2021;22(1):265. 2 Désogere P, et al. Sci Trans Med. 2017;9(384):eaaf4696. 3 Montesi S, et al. Am J Respir Crit Care Med. 2019;200(2):258-261. 4 Zhang W-J, et al. Radiology. 2016;278(3):906-916. 5 Amundsen T, et al. J Magn Reson Imaging. 2000;12(2):224-